Berenberg Bank Increases Haleon (LON:HLN) Price Target to GBX 512

Haleon (LON:HLN) had its price target raised by research analysts at Berenberg Bank from GBX 510 to GBX 512 in a report issued on Thursday,London Stock Exchange reports. The brokerage currently has a “buy” rating on the stock. Berenberg Bank’s price target indicates a potential upside of 35.27% from the company’s current price.

Several other analysts have also recently issued reports on HLN. JPMorgan Chase & Co. upped their target price on shares of Haleon from GBX 315 to GBX 335 and gave the company an “underweight” rating in a research report on Wednesday, November 26th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 450 price target on shares of Haleon in a research report on Wednesday, January 21st. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on Haleon from GBX 340 to GBX 335 and set a “buy” rating on the stock in a research report on Thursday, January 22nd. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of GBX 407.

Haleon Price Performance

Shares of LON HLN traded down GBX 7.70 during midday trading on Thursday, reaching GBX 378.50. 1,775,494,375 shares of the stock traded hands, compared to its average volume of 68,646,672. The company’s 50 day moving average is GBX 385.53 and its 200 day moving average is GBX 367.24. Haleon has a one year low of GBX 325.10 and a one year high of GBX 419.50. The company has a debt-to-equity ratio of 53.60, a current ratio of 0.87 and a quick ratio of 0.93. The stock has a market capitalization of £33.71 billion, a PE ratio of 20.46, a P/E/G ratio of 1.49 and a beta of 0.25.

Haleon (LON:HLN) last announced its quarterly earnings results on Thursday, February 26th. The company reported GBX 18.60 earnings per share for the quarter. Haleon had a net margin of 13.81% and a return on equity of 9.40%. On average, equities research analysts anticipate that Haleon will post 19.5033282 earnings per share for the current year.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.